KETAMINE DERIVATIVES AND COMPOSITIONS THEREOF
Ketamine derivatives and pharmaceutical compositons thereof are disclosed. When administered orally the ketamine derivatives provide increased bioavailability of ketamine in the systemic circulation. The ketamine derivatives can be used to treat neurological diseases, psychological diseases and pain..
| Medienart: |
|
|---|
Patent| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Europäisches Patentamt - (2020) vom: 16. Juli Zur Gesamtaufnahme - year:2020 |
|---|
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
XIANG JIA-NING [VerfasserIn] |
|---|
| Links: |
Volltext [kostenfrei] |
|---|
| Anmerkungen: |
Source: www.epo.org (no modifications made), First posted: 2020-07-16, Last update posted on www.tib.eu: 2023-12-22, Last updated: 2023-12-29 |
|---|
| Patentnummer: |
WO2020143198 |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
EPA005037921 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | EPA005037921 | ||
| 003 | DE-627 | ||
| 005 | 20231229110029.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 210529s2020 xx |||||o 00| ||eng c | ||
| 035 | |a (DE-627)EPA005037921 | ||
| 035 | |a (EPA)WO2020143198 | ||
| 035 | |a (EPA)67218871 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 0 | |a XIANG JIA-NING |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a KETAMINE DERIVATIVES AND COMPOSITIONS THEREOF |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Source: www.epo.org (no modifications made), First posted: 2020-07-16, Last update posted on www.tib.eu: 2023-12-22, Last updated: 2023-12-29 | ||
| 520 | |a Ketamine derivatives and pharmaceutical compositons thereof are disclosed. When administered orally the ketamine derivatives provide increased bioavailability of ketamine in the systemic circulation. The ketamine derivatives can be used to treat neurological diseases, psychological diseases and pain. | ||
| 650 | 4 | |a C07D: Heterocyclic compounds (macromolecular compounds c08) | |
| 650 | 4 | |a A61K: Preparations for medical, dental, or toilet purposes (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms a61j0003000000;chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles a61l; soap compositions c11d) | |
| 650 | 4 | |a A61P: Specific therapeutic activity of chemical compounds or medicinal preparations | |
| 650 | 4 | |a che | |
| 650 | 4 | |a C07C: Acyclic or carbocyclic compounds (macromolecular compounds c08;production of organic compounds by electrolysis or electrophoresis c25b0003000000, c25b0007000000) | |
| 650 | 4 | |a 615 | |
| 700 | 0 | |a XU XUESONG |4 aut | |
| 700 | 0 | |a SHIH HAO-WEI |4 aut | |
| 700 | 0 | |a ENG WAI-SI |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Europäisches Patentamt |g (2020) vom: 16. Juli |
| 773 | 1 | 8 | |g year:2020 |g day:16 |g month:07 |
| 856 | 4 | 0 | |u https://worldwide.espacenet.com/patent/search/family/67218871/publication/WO2020143198A1?q=WO2020143198 |z kostenfrei |3 Volltext |
| 912 | |a GBV_EPA | ||
| 936 | u | w | |j 2020 |b 16 |c 07 |
| 951 | |a AR | ||
| 952 | |j 2020 |b 16 |c 07 | ||